Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fluvax (2015-2016 season formulation) refers to the seasonal influenza vaccine produced under the Fluvax brand for the 2015-2016 influenza season. Influenza vaccines are designed to prevent influenza infection by stimulating the immune system to produce antibodies against specific influenza virus strains. These vaccines typically contain inactivated or weakened forms of the influenza virus antigens. The 2015-2016 formulation, like other seasonal flu vaccines, was available in trivalent (protecting against two A-strains and one B-strain) and quadrivalent (protecting against two A-strains and two B-strains) versions. The effectiveness of the 2014-2015 influenza vaccine, which would have been the preceding season's formulation, was notably low against the predominant A/H3N2 strain due to antigenic drift, where the circulating virus mutated after the vaccine strains were selected. Annual vaccination is necessary due to the continuous evolution of influenza virus strains.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Fluvax (2015-2016 season formulation).